Publications

Cetin K, Callaghan F, Fryzek J, Bylsma L, Bezold C, Mehta B. Safety and efficacy/effectiveness of 2nd-line treatments in Immune Thrombocytopenia (ITP): A systematic review of the literature. Presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 2016.

Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ. 2016. Patient-level costs of major cardiovascular conditions: A review of the international literature. Clinicoecon Outcomes Res 21(8):495-506; doi: 10.2147/CEOR.S89331. PMID: 27703385.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503.

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311. PMID: 27587380.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Cetin K, Callaghan F, Fryzek J, Bylsma L, Bezold C, Mehta B. Safety and efficacy/effectiveness of second-line treatments in patients with Immune Thrombocytopenia: A systematic review of the literature. Presented at the 21st Congress of the European Hematology Association, Copenhagen, Denmark, June 2016.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol 306(Sept 1):113-119; doi: 10.1016/j.taap.2016.07.004. PMID: 27404458.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol 306(Sep 1):120-133; doi: 10.1016/j.taap.2016.07.002. PMID: 27396814.